Law Firms Press MoonLake Class Action Over SLK Claims as Lead‑Plaintiff Deadline Nears
The SDNY case is in its early stages following allegations that MoonLake overstated sonelokimab’s edge over BIMZELX.
Overview
- Levi & Korsinsky says a securities class action has been filed in the Southern District of New York covering investors from March 10, 2024 through September 29, 2025.
- Complaints assert MoonLake misled investors about SLK’s differentiation, alleging it targets the same cytokines as BIMZELX (IL‑17A and IL‑17F) and that the Nanobody design did not deliver superior clinical benefit or meaningful tissue‑penetration advantages.
- Hagens Berman highlights the gap between MoonLake’s statements and Phase 3 VELA week‑16 data, which reportedly showed SLK failed to demonstrate competitive efficacy versus BIMZELX.
- MoonLake’s shares fell about 90% to $6.24 on September 29, 2025 following disclosure of the VELA results.
- Investors have until December 15, 2025 to seek appointment as lead plaintiff, with Hagens Berman, Faruqi & Faruqi, Levi & Korsinsky, and Rosen Law Firm soliciting claims and noting no class has yet been certified.